NGNE (Neurogene Therapeutics) Net earnings per share change in current year
The high degree of scientific intensity and patent protection of Neurogene Inc. (NGNE) eliminate pricing pressure at launch. The annual EPS growth ratio visualizes this potential, where the -22.30 indicator determines the metric's magnitude. The startup is developing breakthrough gene delivery methods to the brain to combat incurable pathologies, and future revenues will be based on the commercialization of Rett syndrome therapy.
Comprehensive metric breakdowns and analytics for Neurogene (NGNE)
- stock value and consensus price forecast:
- business market valuation indicators:
- book value of equity indicators:
- debt burden and liquidity indicators:
Debt to Capital Neurogene Inc.|NGNE - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Neurogene|NGNE - Company Aggregate Debts|Debts to Net Assets Neurogene Inc.|NGNE - Company Long-Term Debt|Company Short-Term Indebtedness Neurogene|Quick Liquidity Indicator neurogene.com
- company profitability and valuation multiples indicators:
NGNE - Net Income|Company Profit Forecast Neurogene Inc.|NGNE - Price to Earnings Ratio|Price to Future Earnings Ratio Neurogene Inc.|NGNE - PEG Multiple|Enterprise Value to EBITDA Multiple Neurogene Inc.|NGNE - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Neurogene|NGNE - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months neurogene.com|NGNE - Earnings per share growth in current year|Projected earnings per share growth rate for next year Neurogene Inc.
- revenue and sales proceeds data:
Fundamental valuation:NGNE - Neurogene Therapeutics
Professional asset selection is based on identifying sustainable trends, where net income per share dynamics serve as the key filter. By analyzing annual earnings per share growth, an investor evaluates the percentage change in EPS compared to the previous year, which for Neurogene Inc. (NGNE) confirms the effectiveness of a production and clinical trial outsourcing model that minimizes capital expenditures.
Main competitors
Earnings per share growth rate in current year Biogen Idec (BIIB)|NBIX (neurocrine.com) - Earnings growth in current year|Earnings per share growth rate in current year regencellbioscience.com RGC|Net earnings per share growth this year AXSM (Axsome Therapeutics, Inc.)|ACAD (ACADIA Pharma) - Earnings per share increase in current year|Earnings growth in current year XENE (Xenon Pharmaceuticals Inc)|Net earnings per one share growth for the current year VKTX (Viking Pharma)|SUPN: Net earnings per share growth this year|Earnings per share increase in current year CPRX (catalystpharma.com)|DNLI: Earnings growth in current year|HRMY - Expected net earnings per share growth this year|Net earnings per share growth this year BHVN|AMLX: Earnings per share increase in current year|Earnings per share growth in current year Trevi Pharma (TRVI)|Expected net earnings per share growth this year praxismedicines.com|Earnings per share growth in current year Anavex AVXL|Expected net earnings per share growth this year CeriBell (CBLL)|PRTA - Earnings per share growth in current year|ALEC: Earnings per share growth in current year|Annexon (ANNX) - Earnings per share growth in current year|OMER: Net earnings per one share growth for the current year|Net earnings per share growth this year ACIU|Earnings growth in current year Voyager Pharma|Net earnings per share growth this year NMRA (Neumora Therapeutics, Inc.)|SCLX - Earnings per share growth rate in current year|Earnings per share growth in current year Tevogen Bio TVGN|Alpha Cognition Corp (ACOG) - Earnings per share growth rate in current year|CGTX: Net earnings per share growth this year|Inhibikase Therapeutics, Inc. - Net earnings per one share growth for the current year|SAVA: Earnings growth in current year|Earnings per share growth this year ASRT|COYA (coyatherapeutics.com) - Earnings growth in current year|Vistagen (VTGN) - Expected net earnings per share growth this year|Net earnings per share growth this year OVID (Ovid Rx)|Expected net earnings per share growth this year Acumen Pharmaceuticals, Inc.|Earnings growth in current year CRVO (CervoMed Corporation)|Net earnings per one share growth for the current year ATHE (Alterity Therapeutics Ltd)|Clene Nanomedicine - Earnings growth in current year|Net earnings per share change in current year pepgen.com (PEPG)|JUNS: Earnings growth in current year|Earnings per share growth this year RLMD|ANVS (Annovis Bio Inc) - Earnings growth in current year|Net earnings per share growth this year Grace Therapeutics, Inc. (GRCE)|Earnings growth in current year AIFF|Net earnings per one share growth for the current year KLTO|Earnings per share growth in current year neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings (RVPH) - Earnings per share growth rate in current year|MetaVia Inc. - Earnings growth in current year|Expected net earnings per share growth this year NeurAxis Inc NRXS|HSDT (Helius Medical Technologies Inc.) - Net earnings per share growth this year|Passage Bio Inc. (PASG) - Earnings growth in current year|Earnings per share growth in current year Neuphoria|Net earnings per share growth this year Minerva Neurosciences, Inc. (NERV)|Earnings per share growth in current year Athira (ATHA)|Addex Therapeutics - Earnings per share growth this year|Earnings per share growth in current year Alzamend Neuro, Inc. ALZN|Cyclerion (CYCN) - Earnings per share growth rate in current year|PTIX - Earnings per share growth in current year|Expected net earnings per share growth this year Pasithea Therapeutics Corp KTTA|Cortigent, Inc. (CRGT) - Earnings per share growth in current year|Avenue Therapeutics - Earnings per share increase in current year|BCLI (brainstorm-cell.com) - Earnings growth in current year|CARA: Earnings per share increase in current year|Earnings per share growth in current year Chromocell Therapeutics Corp (CHRO)|ELYM (Eliem Therapeutics Inc.) - Earnings per share increase in current year|Earnings growth in current year ITCI (Intra-Cellular Therapies Inc.)|Net earnings per share change in current year Longboard Pharma|MRNS - Earnings per share growth in current year|NKGen Biotech, Inc. (NKGN) - Net earnings per share growth this year|NRBO (NeuroBo Pharmaceuticals, Inc.) - Net earnings per share growth this year|Sage Therapeutics - Earnings per share increase in current year|Earnings per share growth in current year Synaptogenix, Inc.|TRVN: Earnings per share increase in current year|Earnings growth in current year VIGL|Net earnings per share growth this year Anew Medical, Inc. WENA|Earnings per share growth in current year Cerevel Therapeutics CERE
